Navigation Links
Interim Data Announced for BIBF 1120 as Compared to bevacizumab in Combination Chemotherapy in Metastatic Colorectal Cancer
Date:9/27/2011

STOCKHOLM, Sept. 27, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced interim results from an exploratory clinical trial evaluating its investigational compound BIBF 1120 in patients with metastatic colorectal cancer (mCRC).  In this Phase I/II study of 126 patients comparing BIBF 1120 as first-line treatment to bevacizumab, both in combination with mFOLFOX6 (6th modified regimen of folinic acid [leucovorin], fluorouracil, and oxaliplatin), the progression-free survival (PFS) rate at 9 months was 63 percent (95% CI: 50%-75%) in the BIBF 1120 arm and 69% (95% CI: 53%-86%) in the bevacizumab arm.(1)  The median PFS was numerically similar between both groups at 10.6 months ([95% CI: 9.4-12.3] for the BIBF 1120 arm and [95% CI: 9.1-NA] for the bevacizumab arm).(2)

The study, presented at the Presidential Session of the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, also showed that the objective response rate (ORR), a measure of tumor shrinkage, was 61 percent in the BIBF 1120 arm and 54 percent in the bevacizumab arm.(1)

While both treatment arms showed similar safety profiles, a lower incidence of serious adverse events was seen in patients taking BIBF 1120 compared to those taking bevacizumab (34% vs. 54%).(2)  Adverse events (grade 3 or higher) experienced by at least 10 percent of patients in the BIBF 1120 and bevacizumab arms included neutropenia (32% vs. 24%), diarrhea (15% vs. 12%), neurotoxicity (14% vs. 10%), paresthesia (13% vs. 12%) and asthenia (11% vs. 10%).(1)  Patients receiving BIBF 1120 experienced a lower frequency of serious gastrointestinal adverse events than those receiving bevacizumab (12% vs. 29%).(2)

The study is ongoing in order to collect overall survival (OS) data. Phase III trials with larger patient populations will be considered to confirm these results and to further investigate the potential of BIBF 1120 in mCRC.

"The study results
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... -- DeepResearchReports.com adds "2014 Deep Research Report on ... Deep Research Report on Global and China Tricalcium ... Photo - http://photos.prnewswire.com/prnh/20140731/132164 ... Global and China Potassium Nitrate  Industry" is a ... China and Global Potassium Nitrate  market. ...
(Date:7/31/2014)... -- IRIDEX Corporation (Nasdaq: IRIX ) today reported ... June 28, 2014.  , Revenues were $10.6 million ... million in the 2013 second quarter and up sequentially from ... the first six months of 2014 were $20.9 million, up ... last year. , Gross margin for the quarter was ...
(Date:7/31/2014)...  Cepheid (NASDAQ: CPHD ) today announced that ... invited investors to participate via webcast. ... NY Wednesday, August 13, 2014 at 9.10 a.m. ... New York, NY Thursday, September 4, 2014 ... Webcasts To access the live webcasts for these events, please ...
Breaking Medicine Technology:Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Cepheid to Webcast Upcoming Financial Presentations 2
... 2011 Surgical Information Systems ("SIS") announced today ... management systems as a key component of the ... Healthcare Information and Management Systems Society, February 20-24 ... presentations and solution demonstrations, SIS will showcase the ...
... Va., Feb. 17, 2011 Radiologic Associates of ... Campaign to increase awareness of opportunities to lower radiation ... of the Alliance for Radiation Safety in Pediatric Imaging.  ... additional training in ways to reduce radiation exposure, especially ...
Cached Medicine Technology:Surgical Information Systems Focuses on Surgery and Anesthesia as a Key Component of the EHR at HIMSS11 2Surgical Information Systems Focuses on Surgery and Anesthesia as a Key Component of the EHR at HIMSS11 3Radiologic Associates of Fredericksburg Announces Image Gently Campaign to 'Child Size' Doses for Children 2
(Date:8/1/2014)... August 01, 2014 Stryker hip ... of the 2012 Rejuvenate and ABG II Modular-Neck ... New Jersey’s Bergen County Superior Court, Bernstein Liebhard ... proceeding, the Court has issued a Final ... and all hard copy and electronic materials produced ...
(Date:8/1/2014)... Almost 140 people die every year in accidents ... But there are several simple ways to ... coordinator at Cincinnati Children,s Hospital Medical Center,s Comprehensive ... news release. "As families begin to prepare ... parents and children to go over school bus ...
(Date:8/1/2014)... York, New York (PRWEB) August 01, 2014 ... http://www.gynecaremorcellatorlawsuit.com/ ) on behalf of women who allegedly experienced ... of power morcellators in gynecological surgeries, Bernstein Liebhard LLP ... to withdraw a number of power morcellators marketed by ... a report from The New York Times, some critics ...
(Date:8/1/2014)... Las Vegas, NV (PRWEB) August 01, 2014 ... issues and opportunities for independent community pharmacies. At ... tradeshow, pharmacists are equipped with practices and resources ... General Session, AmerisourceBergen leaders focused on critical issues ... to learn, optimize and grow. , ThoughtSpot ...
(Date:8/1/2014)... NY, August 1, 2014Lesbian, gay, bisexual, and transgender individuals ... same problems as some of their heterosexual and cisgendered ... often face additional physiological and legal challenges to ... advances in assisted reproduction options is presented in the ... Possibilities ," published in LGBT Health ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Expert Offers School Bus Safety Tips 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2
... 9, 2010) An ultra-low-molecular-weight heparin called semuloparin ... venous thromboembolism in orthopedic surgery patients in a ... committee chaired by McMaster University professor Dr. Alexander ... completed international clinical studies on short-term venous thromboembolism ...
... ... ... bliss is not all it’s cracked up to be. Oh, sure, it’s great while it ... of July sparkler. , , ,Long-lasting, transformational marriages rely on more than passion to thrive, ...
... ... Khoi Nguyen and Dennis McDowell have joined their executive sales staff in the Houston ... the area,s most influential hospitals and providers. Accel is the Company’s top tier network ... providers. , ...
... BUENOS AIRES, ARGENTINA, July 9 Pfizer Inc, the ... of a number of hemophilia studies will be presented ... taking place July 10-14, 2010, in Buenos Aires, Argentina. ... Xa as a potential new approach to restoring hemostasis, ...
... ... nation to receive the “Best Practice” award from Safety Net Solutions. The award recognizes the ... for the communities they serve. , ... (Vocus) July 8, 2010 -- St. Elizabeth’s Dental Clinic is one ...
... ... health problems, Sam’s Club is hosting free health screenings in more than 400 of its ... ... To help its members and community residents detect a range of preventable health problems, Sam’s ...
Cached Medicine News:Health News:Drug study shows improvement in major orthopedic surgery care 2Health News:When the Fireworks Fizzle: How to Stoke the Flames of Lasting Love 2Health News:HealthSmart Adds Experienced Professionals to Houston Sales Force 2Health News:Pfizer Hemophilia presents new data at the World Federation of Hemophilia 2010 Congress 2Health News:St. Elizabeth Dental Clinic Named one of the Best in the Nation 2Health News:Sam's Club Hosts Health Screenings July 10 2
Liquichek Hematology Control (C) is an assayed hematology control for evaluating the performance of Coulter hematology instruments with complete CBC and VCS 5-part differential technology....
... are liquid controls designed to ... procedures that detect Chlamydia trachomatis ... are specimen specific, they can ... or endocervical/urethral swabs throughout the ...
Liquichek Pediatric Control is a product designed to monitor important analytes for neonatal testing. This control monitors four bilirubin parameters at two clinically significant levels....
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Medicine Products: